Inspire Medical Systems, Inc. Common Stock (NY:INSP)

69.48 -0.49 (-0.70%)

Delayed Quote Updated: 11:23 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Inspire Medical Systems, Inc. Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Inspire Medical's Earnings Surge in Q4 ↗

February 10, 2025

The sleep apnea specialist's fourth-quarter results surpassed expectations.

Via The Motley Fool

Inspire Medical Systems’s (NYSE:INSP) Q4: Beats On Revenue

February 10, 2025

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 24.5% year on year to $239.7 million. The company...

Via StockStory

4 Analysts Assess Inspire Medical Systems: What You Need To Know ↗

February 10, 2025

Via Benzinga

Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect

February 09, 2025

Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know.

Via StockStory

Deep Dive Into Inspire Medical Systems Stock: Analyst Perspectives (8 Ratings) ↗

January 24, 2025

Via Benzinga

In the world of growth stocks, NYSE:INSP shines as a value proposition. ↗

November 13, 2024

Despite its growth, NYSE:INSP remains within the realm of affordability.

Via Chartmill

7 Analysts Have This To Say About Inspire Medical Systems ↗

November 05, 2024

Via Benzinga

Why INSPIRE MEDICAL SYSTEMS INC (NYSE:INSP) qualifies as a high growth stock. ↗

October 07, 2024

Exploring INSPIRE MEDICAL SYSTEMS INC (NYSE:INSP)'s high growth characteristics.

Via Chartmill

Earnings Scheduled For February 10, 2025 ↗

February 10, 2025

Via Benzinga

Inspire Medical's Sleep Innovations Driving Big Gains ↗

January 08, 2025

Inspire Medical, which makes innovative apnea relief devices, hit a key performance benchmark as its Relative Strength Rating jumped to 81.

Via Investor's Business Daily

Analyst Scoreboard: 7 Ratings For Inspire Medical Systems ↗

September 30, 2024

Via Benzinga

The Analyst Verdict: Inspire Medical Systems In The Eyes Of 7 Experts ↗

September 10, 2024

Via Benzinga

Deep Dive Into Inspire Medical Systems Stock: Analyst Perspectives (6 Ratings) ↗

July 16, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 27, 2024

Via Benzinga

Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade ↗

November 20, 2024

BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.

Via Benzinga

Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗

September 09, 2024

Via Benzinga

Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday ↗

August 07, 2024

Via Benzinga

What Analysts Are Saying About Inspire Medical Systems Stock ↗

June 24, 2024

Via Benzinga

Expert Ratings For Inspire Medical Systems ↗

June 03, 2024

Via Benzinga

INSP Stock Earnings: Inspire Medical Systems Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

INSP stock results show that Inspire Medical Systems beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

INSPIRE MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Inspire Medical Systems, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 17, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

FDA Labels Inspire Medical's Sleep Apnea Nerve Stimulator Recall As Most Serious ↗

July 09, 2024

Inspire Medical Systems recalls Model 3028 IPG due to manufacturing defect causing serious health risks. Learn about the FDA Class I recall implications and patient advisories.

Via Benzinga

Topics Product Recall

Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market

July 01, 2024

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.

Via MarketBeat

ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday ↗

June 24, 2024

Via Benzinga

Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again ↗

June 24, 2024

Eli Lilly tested its weight-loss drug in people with obesity suffering from sleep apnea events.

Via Investor's Business Daily

Jim Cramer: Celestica Makes A 'Comeback,' Sell This Movie Theater Stock, ↗

May 28, 2024

Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter financial results.

Via Benzinga

7 Undervalued Stocks That Could Triple Your Money by 2026 ↗

May 28, 2024

These seven undervalued stocks have the potential to triple investors' money by 2026 once the market fully recognizes their value.

Via InvestorPlace

Dow Gains 150 Points; Emerson Electric Earnings Top Views ↗

May 08, 2024

Via Benzinga

Topics Stocks

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 08, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 08, 2024

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.